CONMED

CNMD

Market cap $1.04B

CNMD is sharpening its focus on AirSeal, Buffalo Filter and BioBrace, betting on higher-growth platforms to drive margin gains and long-term growth.

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total.

Investors need to pay close attention to CNMD stock based on the movements in the options market lately.

CNMD tops Q1 estimates despite sales dip, lifts 2026 organic growth outlook as strategic shift sharpens focus on higher-growth segments.

CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Conmed (CNMD) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.95 per share a year ago.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decreased 1.3% year-over-year as reported and 2.9% in constant currency. Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products. Domestic revenue decreased 5.8% year-over-year. Domestic sales growth was impacted by a $15.2 million decrease in sales from th.

CNMD's high-margin platforms, supply-chain recovery and margin expansion plans support growth, though tariffs and portfolio shifts weigh on near-term results.